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Abstract
Background and Aim: Familial Mediterranean fever (FMF) is an autosomal recessive
disease characterised by recurrent episodes of painful inﬂammation in the abdomen,
chest or joints. The association between FMF and non-amyloid glomerulopathies are
unusual. In this study, we describe our experiences and observations about renal
involvement in patients with FMF.
Methods: A total of 108 patients with FMF was enrolled in the study. Twelve patients
with FMF were referred to the Nephrology Service, for evaluation and assessment of the
degree of renal involvement. All the 12 patients underwent percutaneous ultrasound-
guided renal biopsies and genetic analysis.
Results: On microscopic examination of the kidney specimens, six patients were found
to have amyloidosis, ﬁve focal segmental glomerulosclerosis and one patient
membranoproliferative glomerulonephritis. It seems that in patients with FMF and renal
amyloidosis, the response to treatment with colchicine is excellent, but in patients
with FMF and focal segmental glomerulosclerosis, the response to treatment with
colchicine is poor. We present an evidence-based algorithm, constructed based on
literature review, to aid decision making in management of renal involvement in
patients with FMF.
Conclusion: The results of our study suggest that in patients with FMF and renal
involvement, non-amyloid renal lesions should be considered in the differential diag-
nosis in addition to amyloidosis.
Introduction
Familial Mediterranean fever (FMF) is an autosomal
recessive disease characterised by recurrent episodes of
painful inﬂammation in the abdomen, chest or joints.
These episodes are often accompanied by fever and
sometimes a rash.1 Most patients with FMF experience
their ﬁrst attack in early childhood; in 65% of cases, the
initial attack occurs before the age of 10 years, and in
90% before the age of 20 years.2 FMF primarily affects
populations originating in the Mediterranean region, par-
ticularly people of Armenian, Arab, Turkish and non-
Ashkenazi Jewish ancestry.3 The prevalence is 1 in 256
people to 1 in 500 people among non-Ashkenazi Jews,4
and 1 in 1073 people among the Turkish population.5 The
FMF gene, also named as Mediterranean Fever (MEFV)
gene, is located on the short arm of chromosome 16.6
FMF is caused by a mutation in the gene encoding pyrin.
The exact mechanism triggering the acute attacks in FMF
is unclear, but several lines of evidence point to the
neutrophil as the effector of the inﬂammatory response at
serosal surfaces.
Renal involvement is the dominant feature of FMF-
related amyloidosis. It begins insidiously, causing pro-
teinuria, then progresses to symptomatic nephrotic
syndrome, and eventually ends in renal failure. The
natural history of amyloidotic nephropathy in FMF is
such that end-stage renal disease develops from 2 to 13
years after the onset of proteinuria.2 Although the
inﬂammatory attacks of untreated FMF are the cause of
much morbidity, the major source of mortality in this
disease is progressive secondary (AA) amyloidosis.7
Before the advent of colchicine, amyloidosis occurred in
approximately 30% of Sephardic Jews and 60% of Turks
with FMF.1 Amyloidosis is much less common in Ashke-
nazi Jews and FMF patients living in America, including
those of Armenian ancestry.8
The association between FMF and non-amyloid
glomerulopathies is unusual. In the present study, we
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